Mr. Shane Madden reports

HYDREIGHT PROVIDES BUSINESS UPDATE ON ITS PEPTIDE HEALTHCARE PLATFORM FOLLOWING RECENT FDA ADVISORY COMMITTEE RECOMMENDATIONS

Hydreight Technologies Inc. today provided an update on its peptide health care platform following the recent recommendations of the United States Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC).

During its July 23 to July 24, 2026, meeting, the PCAC recommended that six peptide-related bulk drug substances -- BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon -- be considered for inclusion on the FDA's Section 503A Bulks List. These recommendations are advisory only, do not constitute FDA approval of any substance or finished drug product and remain subject to the FDA's rule-making process.

Management considers these recommendations material because peptide-based therapies already represent a significant component of Hydreight's existing business. Through its physician-supervised health care platform, the company currently supports multiple peptide-based treatment categories and has made substantial investments in physician infrastructure, pharmacy relationships, clinical protocols and technology supporting peptide-based care.

"The recent PCAC recommendations are meaningful because they relate to a therapeutic category where Hydreight already operates today," said Shane Madden, chief executive officer of Hydreight. "We've spent years building the physician, pharmacy and technology infrastructure supporting peptide-based health care. The recommendations don't change our strategy -- they reinforce why we've been investing in this category for years while continuing to focus on compliant, physician-supervised care."

Peptide-based medicine is already an established part of Hydreight's business

The company currently supports multiple physician-supervised peptide-based treatment categories through its nationwide physician, pharmacy and technology platform, including GLP-1 therapies, Sermorelin and Ipamorelin. These peptide-based therapies form part of Hydreight's broader personalized health care platform, which also includes hormone optimization, NAD+ therapies, IV wellness, sexual health, hair restoration and other physician-supervised health care programs.

Platform expansion driven by existing peptide business

Hydreight's peptide health care platform has been under development since 2019 and reflects the company's long-term strategy of building a nationwide physician-enabled health care infrastructure supporting compliant personalized health care.

Since 2019, Hydreight has continued investing in its physician, pharmacy and technology infrastructure with the objective of building a scalable platform capable of supporting physician-supervised personalized health care across the United States.

Today, the company's health care ecosystem includes:

• More than 12,000 VSDHOne licences sold, compared to approximately 3,000 at the end of 2025;
• A nationwide network of 300-plus licensed physicians;
• More than 3,000 licensed nurses operating through the Hydreight platform;
• A nationwide pharmacy network supporting physician-supervised health care programs across all 50 U.S. states;
• More than 45 physician-supervised treatment offerings spanning GLP-1 therapies, peptide-based treatments, hormone optimization, NAD+ therapies, IV wellness, sexual health, hair restoration and other personalized health care programs offered through the VSDHOne platform;
• Proprietary technology supporting patient onboarding, telehealth consultations, electronic prescribing, pharmacy co-ordination, payment processing and continuing patient management.

The investments described above were undertaken as part of Hydreight's long-term platform strategy and were not initiated in response to the recent PCAC recommendations.

This infrastructure was developed well before the recent PCAC recommendations and supports peptide-based therapies currently available through the company's platform. It also provides the operational foundation to evaluate additional physician-supervised treatment categories should future regulatory pathways permit their introduction, subject to applicable legal, clinical and regulatory requirements.

As part of these investments, Hydreight has completed medical policies, provider protocols and VSDHOne technology workflows supporting currently available physician-supervised peptide-based treatment categories, while also expanding pharmacy relationships and fulfilment capacity supporting compliant nationwide health care delivery.

Clinical, pharmacy and technology infrastructure

As peptide-based health care has become a larger component of Hydreight's business, the company has continued investing in infrastructure supporting physician-supervised treatment categories.

Completed initiatives include:

• Development and implementation of medical policies;
• Completion of provider protocols;
• Expansion of VSDHOne technology workflows;
• Expansion of pharmacy relationships and fulfilment capacity;
• Clinical co-ordination supporting physician-supervised peptide health care.

These initiatives support treatment categories currently available through the platform while also providing operational readiness should additional physician-supervised therapies become legally available in the future.

Existing peptide strategy

Hydreight's peptide health care platform includes physician-supervised GLP-1 therapies, Sermorelin, Ipamorelin and other peptide-based treatment categories delivered through the company's nationwide physician, pharmacy and technology infrastructure.

The company has continued expanding this platform through investments in clinical protocols, provider workflows, pharmacy relationships and VSDHOne technology, providing the operational foundation to support compliant physician-supervised peptide-based health care.

Hydreight's strategy extends beyond its currently available treatment categories. Earlier this year, the company announced its strategic investment in Insu Therapeutics Inc., a biotechnology company developing proprietary buccal drug delivery technology for peptide and biologic medicines.

Together, Hydreight's existing peptide-based treatment categories, nationwide physician and pharmacy infrastructure, VSDHOne platform and investment in Insu Therapeutics reflect the company's long-term strategy of building an integrated healthcare platform supporting physician-supervised personalized medicine.

FDA advisory committee recommendations

During its July 23 to July 24 meeting, the PCAC recommended six peptide-related bulk substances for potential inclusion on the Section 503A Bulks List:

• BPC-157;
• KPV;
• TB-500;
• MOTS-c;
• Semax;
• Epitalon.

The committee did not recommend Emideltide (DSIP).

The recommendations relate solely to potential inclusion on the Section 503A Bulks List and do not constitute FDA approval.

Hydreight notes that any future implementation of products involving these substances would remain subject to applicable FDA rule-making, federal and state regulations, physician oversight, pharmacy participation, and product-specific legal and clinical review.

Looking ahead

Hydreight will continue executing its long-term strategy of expanding its physician, pharmacy and technology infrastructure supporting currently available treatment categories while evaluating additional physician-supervised therapies in accordance with applicable legal, clinical and regulatory requirements.

About Hydreight Technologies Inc.

Hydreight Technologies is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3,000 nurses, over 300 doctors and a pharmacy network through its doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking and managing patient data, which enables licensed health care professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed health care professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a United States-certified e-script and telemedicine provider network.

About VSDHOne -- direct-to-consumer platform

Developed in partnership with Victory Square Technologies (Canadian Securities Exchange: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne platform. VSDHOne aims to simplify the entry challenges for companies and medi-spa businesses to enter the on-line health care space compliantly. This platform is expected to help businesses launch direct-to-consumer health care brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized health care treatments, sermorelin, testosterone replacement therapy (TRT), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer health care brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the on-line health care space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

We seek Safe Harbor.